Compare $MBRX vs $OTLC | Chartloom

Compare

$MBRX vs $OTLC

Moleculin Biotech Inc · Oncotelic Therapeutics Inc

MBRX

Moleculin Biotech Inc

OTLC

Oncotelic Therapeutics Inc

Compare $MBRX vs $OTLC

Comparing Moleculin Biotech Inc and Oncotelic Therapeutics Inc

MBRXMoleculin Biotech Inc

OTLCOncotelic Therapeutics Inc

MBRXMoleculin Biotech Inc

Market cap

$3M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-87.8%

52W performance

-96.5%

FCF yield

-811.4%

OTLCOncotelic Therapeutics Inc

Market cap

$9M

P/E (TTM)

0.04x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-74.0%

52W performance

-76.9%

FCF yield

-16.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

MBRX

OTLC

Detailed metrics comparison

MBRX

Moleculin Biotech Inc

OTLC

Oncotelic Therapeutics Inc

Market Cap

MBRX$3M

OTLC$9M

Enterprise Value

MBRX$-4M

OTLC$23M

Price

MBRX$0.44

OTLC$0.02

P/E Ratio

MBRXN/A

OTLC0.04x

P/S Ratio

MBRX0.00x

OTLC36.91x

EV/Sales

MBRX0.00x

OTLC91.75x

EV/EBITDA

MBRX0.00x

OTLC0.00x

P/B Ratio

MBRX0.86x

OTLC0.04x

P/FCF Ratio

MBRXN/A

OTLCN/A

EV/FCF

MBRX0.16x

OTLC-15.05x

PEG Ratio

MBRXN/A

OTLCN/A

Forward P/E (NTM)

MBRXN/A

OTLCN/A

Forward P/S (NTM)

MBRXN/A

OTLCN/A

Revenue (TTM)

MBRX$0

OTLC$250K

Revenue Growth (YoY)

MBRXN/A

OTLCN/A

Forward Rev Growth

MBRX131.1%

OTLC0.0%

Gross Margin (TTM)

MBRX0.0%

OTLC83.1%

Operating Margin (TTM)

MBRX0.0%

OTLC0.0%

EBITDA Margin (TTM)

MBRX0.0%

OTLC-1545.3%

Net Margin (TTM)

MBRX0.0%

OTLC99875.6%

FCF Margin (TTM)

MBRXN/A

OTLC-609.8%

Net Income (TTM)

MBRX$-33M

OTLC$250M

FCF (TTM)

MBRX$-25M

OTLC$-2M

EPS (TTM)

MBRX-$5.73

OTLC$0.53

ROE (TTM)

MBRX-3539.0%

OTLC139.7%

ROA (TTM)

MBRX-13955.0%

OTLC91.8%

ROIC (TTM)

MBRX-3539.0%

OTLC129.6%

Cash

MBRX$7M

OTLC$186K

Debt

MBRX$0

OTLC$14M

Net Cash/Debt

MBRX$7M

OTLC$-14M

Current Ratio (TTM)

MBRX0.94x

OTLC0.08x

Quick Ratio (TTM)

MBRX0.78x

OTLC0.01x

Debt/Equity (TTM)

MBRX0.00x

OTLC0.05x

Debt/Assets (TTM)

MBRX0.0%

OTLC0.0%

Interest Coverage (TTM)

MBRXN/A

OTLCN/A

Net Debt/EBITDA (TTM)

MBRX0.00x

OTLC0.00x

Beta

MBRX2.10

OTLC-0.07

52W Performance

MBRX-96.5%

OTLC-76.9%

YTD Performance

MBRX-87.8%

OTLC-74.0%

% from 52W High

MBRX-97.2%

OTLC-81.1%

% from 52W Low

MBRX173.9%

OTLC4.0%

Asset Turnover (TTM)

MBRX0.00x

OTLC0.00x

FCF Yield (TTM)

MBRX-811.4%

OTLC-16.5%

Earnings Yield (TTM)

MBRX-1040.8%

OTLC2706.0%

Dividend Yield (TTM)

MBRXN/A

OTLCN/A

Rule of 40

MBRX0.0

OTLC-609.8

EV/GP/RG

MBRXN/A

OTLCN/A

Ticker research

View MBRX research View OTLC research

Metric	MBRX Moleculin Biotech Inc	OTLC Oncotelic Therapeutics Inc
Market & Valuation
Market Cap	$3M	$9M
Enterprise Value	$-4M	$23M
Price	$0.44	$0.02
P/E Ratio	N/A	0.04x
P/S Ratio	0.00x	36.91x
EV/Sales	0.00x	91.75x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.86x	0.04x
P/FCF Ratio	N/A	N/A
EV/FCF	0.16x	-15.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$250K
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	131.1%	0.0%
Profitability
Gross Margin (TTM)	0.0%	83.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1545.3%
Net Margin (TTM)	0.0%	99875.6%
FCF Margin (TTM)	N/A	-609.8%
Net Income (TTM)	$-33M	$250M
FCF (TTM)	$-25M	$-2M
EPS (TTM)	-$5.73	$0.53
ROE (TTM)	-3539.0%	139.7%
ROA (TTM)	-13955.0%	91.8%
ROIC (TTM)	-3539.0%	129.6%
Financial Health
Cash	$7M	$186K
Debt	$0	$14M
Net Cash/Debt	$7M	$-14M
Current Ratio (TTM)	0.94x	0.08x
Quick Ratio (TTM)	0.78x	0.01x
Debt/Equity (TTM)	0.00x	0.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.10	-0.07
52W Performance	-96.5%	-76.9%
YTD Performance	-87.8%	-74.0%
% from 52W High	-97.2%	-81.1%
% from 52W Low	173.9%	4.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-811.4%	-16.5%
Earnings Yield (TTM)	-1040.8%	2706.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-609.8
EV/GP/RG	N/A	N/A
Ticker research	View MBRX research	View OTLC research

Valuation

P/E Ratio

OTLC

0.04x

P/S Ratio

MBRX

0.00x

OTLC

36.91x

EV/FCF

OTLC

-15.05x

MBRX

0.16x

Growth & revenue

Forward Revenue Growth

MBRX

131.1%

OTLC

0.0%

Profitability & performance

Gross Margin

OTLC

83.1%

MBRX

0.0%

ROE

OTLC

139.7%

MBRX

-3539.0%

FCF Yield %

OTLC

-16.5%

MBRX

-811.4%

52-Week Performance

OTLC

-76.9%

MBRX

-96.5%

Detailed metrics comparison

MBRX

Moleculin Biotech Inc

OTLC

Oncotelic Therapeutics Inc

Market Cap

MBRX$3M

OTLC$9M

Enterprise Value

MBRX$-4M

OTLC$23M

Price

MBRX$0.44

OTLC$0.02

P/E Ratio

MBRXN/A

OTLC0.04x

P/S Ratio

MBRX0.00x

OTLC36.91x

EV/Sales

MBRX0.00x

OTLC91.75x

EV/EBITDA

MBRX0.00x

OTLC0.00x

P/B Ratio

MBRX0.86x

OTLC0.04x

P/FCF Ratio

MBRXN/A

OTLCN/A

EV/FCF

MBRX0.16x

OTLC-15.05x

PEG Ratio

MBRXN/A

OTLCN/A

Forward P/E (NTM)

MBRXN/A

OTLCN/A

Forward P/S (NTM)

MBRXN/A

OTLCN/A

Revenue (TTM)

MBRX$0

OTLC$250K

Revenue Growth (YoY)

MBRXN/A

OTLCN/A

Forward Rev Growth

MBRX131.1%

OTLC0.0%

Gross Margin (TTM)

MBRX0.0%

OTLC83.1%

Operating Margin (TTM)

MBRX0.0%

OTLC0.0%

EBITDA Margin (TTM)

MBRX0.0%

OTLC-1545.3%

Net Margin (TTM)

MBRX0.0%

OTLC99875.6%

FCF Margin (TTM)

MBRXN/A

OTLC-609.8%

Net Income (TTM)

MBRX$-33M

OTLC$250M

FCF (TTM)

MBRX$-25M

OTLC$-2M

EPS (TTM)

MBRX-$5.73

OTLC$0.53

ROE (TTM)

MBRX-3539.0%

OTLC139.7%

ROA (TTM)

MBRX-13955.0%

OTLC91.8%

ROIC (TTM)

MBRX-3539.0%

OTLC129.6%

Cash

MBRX$7M

OTLC$186K

Debt

MBRX$0

OTLC$14M

Net Cash/Debt

MBRX$7M

OTLC$-14M

Current Ratio (TTM)

MBRX0.94x

OTLC0.08x

Quick Ratio (TTM)

MBRX0.78x

OTLC0.01x

Debt/Equity (TTM)

MBRX0.00x

OTLC0.05x

Debt/Assets (TTM)

MBRX0.0%

OTLC0.0%

Interest Coverage (TTM)

MBRXN/A

OTLCN/A

Net Debt/EBITDA (TTM)

MBRX0.00x

OTLC0.00x

Beta

MBRX2.10

OTLC-0.07

52W Performance

MBRX-96.5%

OTLC-76.9%

YTD Performance

MBRX-87.8%

OTLC-74.0%

% from 52W High

MBRX-97.2%

OTLC-81.1%

% from 52W Low

MBRX173.9%

OTLC4.0%

Asset Turnover (TTM)

MBRX0.00x

OTLC0.00x

FCF Yield (TTM)

MBRX-811.4%

OTLC-16.5%

Earnings Yield (TTM)

MBRX-1040.8%

OTLC2706.0%

Dividend Yield (TTM)

MBRXN/A

OTLCN/A

Rule of 40

MBRX0.0

OTLC-609.8

EV/GP/RG

MBRXN/A

OTLCN/A

Ticker research

View MBRX research View OTLC research

Metric	MBRX Moleculin Biotech Inc	OTLC Oncotelic Therapeutics Inc
Market & Valuation
Market Cap	$3M	$9M
Enterprise Value	$-4M	$23M
Price	$0.44	$0.02
P/E Ratio	N/A	0.04x
P/S Ratio	0.00x	36.91x
EV/Sales	0.00x	91.75x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.86x	0.04x
P/FCF Ratio	N/A	N/A
EV/FCF	0.16x	-15.05x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$250K
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	131.1%	0.0%
Profitability
Gross Margin (TTM)	0.0%	83.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1545.3%
Net Margin (TTM)	0.0%	99875.6%
FCF Margin (TTM)	N/A	-609.8%
Net Income (TTM)	$-33M	$250M
FCF (TTM)	$-25M	$-2M
EPS (TTM)	-$5.73	$0.53
ROE (TTM)	-3539.0%	139.7%
ROA (TTM)	-13955.0%	91.8%
ROIC (TTM)	-3539.0%	129.6%
Financial Health
Cash	$7M	$186K
Debt	$0	$14M
Net Cash/Debt	$7M	$-14M
Current Ratio (TTM)	0.94x	0.08x
Quick Ratio (TTM)	0.78x	0.01x
Debt/Equity (TTM)	0.00x	0.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.10	-0.07
52W Performance	-96.5%	-76.9%
YTD Performance	-87.8%	-74.0%
% from 52W High	-97.2%	-81.1%
% from 52W Low	173.9%	4.0%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-811.4%	-16.5%
Earnings Yield (TTM)	-1040.8%	2706.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-609.8
EV/GP/RG	N/A	N/A
Ticker research	View MBRX research	View OTLC research